Joern Klinger's guest appearances

Joern Klinger

The Alldus Podcast - AI in Action

Chris Hutchins

John Collins

Kevin Johnson

Adam Wenchel

Kraft Heinz

Sean McDermott

Levi Strauss

Jason King

Jenny Zhang

Martin Miller

Gary Beasley

Rich Jones

Nick Adams

Charles Taylor

Brad Taylor

OwlTail

Today's guest is Joern Klinger, CEO and Co-Founder at biotx.ai in Berlin. Founded in 2017, biotx.ai delivers predictive biomarkers as a basis for decision support in precision medicine. They use novel, state of the art, machine learning approaches specifically designed to find complex patterns in biomedical data. biotx.ai has the only AI specifically designed to make wide data manageable. Using graphs of contextual knowledge about metabolic pathways, protein co-expression and protein-protein interactions, they are able to separate the meaningful features from the noise. This allows them to apply all the benefits of big data to wide genomic data. In the show, Joern will tell you about: The motivation for setting up Biotx, Developing a new strategy in response to COVID-19, How Biotx stand out from the competition, Challenges they need to overcome within drug discovery, Transitioning from research into a business-focused startup, Interesting use cases of their work in production, and New trends and breakthroughs within biomedicine

Today's guest is Joern Klinger, CEO and Co-Founder at <a href="http://biotx.ai/" rel="noopener nofollow" target="_blank">biotx.ai</a> in Berlin. Founded in 2017, <a href="http://biotx.ai" rel="nofollow" target="_blank">biotx.ai</a> delivers predictive biomarkers as a basis for decision support in precision medicine. They use novel, state of the art, machine learning approaches specifically designed to find complex patterns in biomedical data. <a href="http://biotx.ai" rel="nofollow" target="_blank">biotx.ai</a> has the only AI specifically designed to make wide data manageable. Using graphs of contextual knowledge about metabolic pathways, protein co-expression and protein-protein interactions, they are able to separate the meaningful features from the noise. This allows them to apply all the benefits of big data to wide genomic data. In the show, Joern will tell you about: The motivation for setting up Biotx, Developing a <a href="https://biotxai.ghost.io/covid-19-strategy/" rel="noopener nofollow" target="_blank">new strategy in response to COVID-19</a>, How Biotx stand out from the competition, Challenges they need to overcome within drug discovery, Transitioning from research into a business-focused startup, Interesting use cases of their work in production, and New trends and breakthroughs within biomedicine

E84 Joern Klinger, CEO and Co-Founder at biotx.ai